Co-oximetry
[Co-oximetry ]
EPTIS Ringversuch Nr. 142512 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142512 https://www.eptis.bam.de/pts142512
| Name des Anbieters | ||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||
| Sprache(n) | ||||||||||||||||
| Anmerkungen | The material is a blood-based matrix containing the 4 major haemoglobin derivates and unlike dyes provided by other EQA providers has equivalent spectral properties to whole blood. Compatible with all major Co-oximeters. Panel covers clinically relevant ranges. Packaged in an easy to use dual-chambered vial that separates the oxyhemoglobin from methemoglobin to enhance stability. Three aqueous samples are distributed monthly, with a minimum of 33 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Panel covers clinically relevant range. - Easy to use vials with minimal preparation time. - Material contains the 4 major haemoglobin derivates and unlike dyes has equivalent spectral properties to whole blood. - Compatible with all major Cooximeters. For more information: https://www.weqas.com/services/eqa/Co-oximetry/ or contact@weqas.com | |||||||||||||||
| Klassifizierung | ||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||
| Technische Einzelheiten | ||||||||||||||||
|
||||||||||||||||
| Ringversuchsziele | ||||||||||||||||
| Zielgruppe des Ringversuchs | The Programme is available to both Laboratory and Point of Care testing sites. The Programme aims to assess the performance of organisations utilising blood gas analysers for the analysis of the patients’ haemoglobin and co-oximetry status. | |||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||
| Teilnehmerzahl | ||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||
| Kosten | ||||||||||||||||
| Teilnahmegebühr | Fee dependent on number of participating sections and proximetry of testing methods. | |||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 2.0mL) | |||||||||||||||
| Der Ringversuch wird durchgeführt seit | 1994 | |||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.